SOURCE: Healthmed Services, Ltd.

August 02, 2011 08:30 ET

HealthMed Services, Ltd. Cites Progress in the Development of At-Home Diabetes Testing

TEMECULA, CA--(Marketwire - Aug 2, 2011) - HealthMed Services, Ltd. (PINKSHEETS: HEME) is pleased to announce that it is continuing development of its at-home test for monitoring glucose control in diabetic and pre-diabetic individuals. Statistics show that there are approximately 10 million people in the US that have confirmed diabetes, of which 90-95 percent are type-2 diabetes, and an equal number that have diabetes but do not know they are diabetic. Many of these individuals would benefit from the in-home test that HealthMed Services is currently developing.

"Diabetes is a devastating disease with tremendous medical and economic costs to an individual with diabetes, the family and the community," said Henry Smith, CEO of HealthMed Services. Dr. Smith continued, "The good news is that type-2 diabetes is the type of diabetes that can be controlled by changing to a healthy life-style. A sensible diet with plenty of exercise can work wonders. However, glucose monitoring is also a critical factor. HealthMed Services is developing a test that will do just that. We are developing a convenient mail-in test where a consumer can send a sample of saliva to a central laboratory that will test the sample for an indicator protein, glycated albumin. Too much glycated albumin means that you are not doing enough to stay healthy and you should make life-style changes to bring the level back into the healthy, normal range."

Dr. Smith added, "There are no good tests currently available for monitoring glucose control in type-2 diabetics. Instead of pricking yourself multiple times a day to test the blood sample for glucose levels, the glycated albumin test is done on a saliva sample that is collected once a month for testing. Our test is also a more direct indicator of how much damage is actually being done to the proteins in your body. Another advantage in developing this non-invasive test is that there are a large number of people who do not realize that they have diabetes, or are at risk of developing diabetes, and these individuals may take advantage of using a test that is convenient, painless and affordable. There is going to be an epidemic of diabetes in the US and other countries unless we can identify early diabetes and take simple and sensible measures to prevent and control this disease. We believe that more education on diabetes, including the use of our glycated albumin test in any diagnostic and treatment regimen, could play a significant role in controlling this disease."

About HealthMed Services, Ltd.

HealthMed Services, Ltd. has acquired the intellectual property rights to two important medical technologies. In the field of Organ Transplantation the Company is developing a device for keeping isolated donor organs alive for extended periods of time outside the body. This will allow the donor organ to be transported across the country to allow better donor and patient matching. Also the better the donor organ can be preserved the better will be the outcome of the organ transplantation. In the field of Diabetes Testing, the Company has developed a saliva test for monitoring glucose control in diabetes. Both diabetics and pre-diabetics will be able to mail a saliva sample to a laboratory that will perform the test and record the result. Patients will be able to access their results in private using the Internet.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with cleaning fluid and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report, quarterly reports or current reports filed from time-to-time with OTC Markets, Inc.

Contact Information

  • Contact:
    Richard E. Floegel
    (619) 248-6868